Joshi L R, Weintraub B D
Endocrinology. 1983 Dec;113(6):2145-54. doi: 10.1210/endo-113-6-2145.
We have examined the interaction of certain forms of mouse (m) tumor and bovine (b) pituitary TSH with standard bTSH on the activation of adenylate cyclase in human thyroid membranes. Tumor extract, serum from tumor-bearing mice, culture medium from dispersed cell incubations, and two preparations of purified bTSH (Sigma and Pierce) were fractionated on Sephadex G-100 (1.2 X 200 cm). For each fraction, TSH bioactivity was measured by stimulation of adenylate cyclase activity in human thyroid membranes, and immunoactivity was determined by RIA. On G-100, Pierce bTSH had multiple immunoactive components with partition coefficients (Kav) of 0.28-0.32 and ratios of biological over immunological activity (B/I) of 0.59-1.42. Sigma bTSH, mouse tumor, serum, and medium were even more heterogeneous (Kav = 0.23-0.32), with a lower range of B/I (0.04-1.0). When single doses (125-2000 ng) of those fractions with the highest Kav (0.30-0.32) and lowest B/I (0.04-0.51) were mixed with multiple doses (200-10,000 microU) of Armour TSH standard (B/I = 1), there was 30-56% inhibition of adenylate cyclase activity stimulation. Double reciprocal plots showed competitive inhibition for the low B/I forms from all sources, except for a medium form which showed mixed inhibition. The medium form had the highest inhibitory activity. There were no inhibitors in G-100 fractions from the Kav regions devoid of TSH immunoactivity or from the same Kav regions of normal mouse serum. To determine the chemical differences between different forms, affinity chromatography on Concanavalin A, wheat germ agglutinin, and soybean agglutinin was employed. Compared with the apparent higher molecular weight form with higher B/I, the apparent lower molecular weight form with lower B/I contained decreased amounts or availability of alpha-mannose and increased amounts or availability of beta-N-acetyl-D-galactosamine and/or beta-galactose; both forms appear to contain similar beta-N-acetyl-D-glucosamine residues, presumably in the inner core.
我们研究了某些形式的小鼠(m)肿瘤和牛(b)垂体促甲状腺激素(TSH)与标准牛TSH对人甲状腺膜中腺苷酸环化酶激活的相互作用。肿瘤提取物、荷瘤小鼠血清、分散细胞培养物的培养基以及两种纯化的牛TSH制剂(Sigma和Pierce)在Sephadex G - 100(1.2×200 cm)上进行分级分离。对于每个级分,通过刺激人甲状腺膜中的腺苷酸环化酶活性来测量TSH生物活性,并通过放射免疫分析(RIA)测定免疫活性。在G - 100上,Pierce牛TSH有多个免疫活性成分,分配系数(Kav)为0.28 - 0.32,生物学活性与免疫活性之比(B/I)为0.59 - 1.42。Sigma牛TSH、小鼠肿瘤、血清和培养基的异质性更强(Kav = 0.23 - 0.32),B/I范围更低(0.04 - 1.0)。当将单剂量(125 - 2000 ng)的那些Kav最高(0.30 - 0.32)且B/I最低(0.04 - 0.51)的级分与多剂量(200 - 10,000微单位)的Armour TSH标准品(B/I = 1)混合时,腺苷酸环化酶活性刺激受到30 - 56%的抑制。双倒数图显示,除了一种表现为混合抑制的培养基形式外,所有来源的低B/I形式均为竞争性抑制。培养基形式的抑制活性最高。在缺乏TSH免疫活性的Kav区域的G - 100级分或正常小鼠血清的相同Kav区域中没有抑制剂。为了确定不同形式之间的化学差异,采用了伴刀豆球蛋白A、麦胚凝集素和大豆凝集素亲和层析法。与具有较高B/I的表观较高分子量形式相比,具有较低B/I的表观较低分子量形式含有较少的α - 甘露糖量或可用性,以及较多的β - N - 乙酰 - D - 半乳糖胺和/或β - 半乳糖量或可用性;两种形式似乎都含有相似的β - N - 乙酰 - D - 葡萄糖胺残基,大概在内核中。